



2021 Biomedical
Symposium

Immunotherapy for Pediatric Cancer: Translating Discoveries into Cures


**October 8, 2021 and
October 15, 2021**

HOSTS

Michael Bishop, MD
Stephen Gottschalk, MD
Paul Thomas, PhD

ORGANIZING COMMITTEE:

Doug Green, PhD
Benjamin Youngblood, PhD
Giedre Krenciute, PhD



OVERVIEW

PEDIATRIC IMMUNO- ONCOLOGY WAS ONCE VIEWED AS AN EXPERIMENTAL OR EMERGING SCIENCE.

However, over the last decade several immunotherapies for pediatric cancers have been FDA-approved including CD19-specific CAR T-cells for acute lymphoblastic leukemia and GD2-specific antibodies for neuroblastoma. We are just beginning to understand the biology of what makes a pediatric tumor amenable to immune control, and how to identify the appropriate tumor-associated features that we can safely target. Thus, there is continued need for discovery-based research, in particular to define the immune landscapes of pediatric cancers and to fully characterize their immune microenvironment. Likewise, there is a need to strengthen translational research focused on mechanisms of immunotherapeutic resistance, and explore combinatorial immunotherapeutic approaches. The 16th St. Jude Children's Research Hospital Biomedical Symposium will bring together six leading experts in fields of immuno-oncology and cell therapy to discuss several exciting new discoveries and the remaining challenges in the field.

October 8, 2021

Day 1

Program

TIME	EVENT	PRESENTER
8:25AM - 8:30 AM	Opening Remarks	Giedre Krenciute, PhD
8:30 - 9:25 AM	A Path Towards Successful T Cell Therapy for Solid Cancers (40 min) 15 min Q&A	Patrick Hwu, MD President & CEO Moffitt Cancer Center
9:25 - 10:20 AM	Understanding Resistance to Expand Immunotherapy Efficacy (40 min) 15 min Q&A	Thomas Gajewski, MD, PhD AbbVie Foundation Professor of Cancer Immunotherapy University of Chicago School of Medicine
10:20 - 10:35 AM	Break	
10:35 - 11:30 AM	CAR-T cells for Pediatric Solid Tumors: Progress and Challenges (40 min) 15 min Q&A	Crystal Mackall, MD Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine Director, Stanford Center for Cancer Cell Therapy Director, Parker Institute for Cancer Immunotherapy at Stanford Co-Executive Director, Stanford Laboratory for Cell & Gene Medicine Associate Director, Stanford Cancer Institute Stanford University
11:30 AM - 12:00 PM	Roundtable Discussion	Patrick Hwu, MD; Thomas Gajewski, MD, PhD; Crystal Mackall, MD, Giedre Krenciute, PhD; Paul Thomas, PhD; Michael Bishop, MD

October 15, 2021

Day 2

Program

TIME	EVENT	PRESENTER
8:25AM - 8:30 AM	Opening Remarks	Doug Green, PhD
8:30 - 9:25 AM	Epigenetic Fate Programming of Living Drugs (40 min) 15 min Q&A	Michel Sadelain, MD, PhD Director, Center for Cellular Engineering Memorial Sloan Kettering Cancer Center
9:25 - 10:20 AM	Turning Up the Heat on Pancreatic Tumors: Lessons Learned on Overcoming A “Cold” Immunologic Tumor Micro-Environment (40 min) 15 min Q&A	Elizabeth Jaffee, MD Dana and Albert ‘Cubby’ Broccoli Professor of Oncology Deputy Director, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University
10:20 - 10:35 AM	Break	
10:35 - 11:30 AM	How Tumor Cells Recognize and Target Tumor Cells (40 min) 15 min Q&A	Timothy Chan, MD, PhD Chair, Center for Immunotherapy & Precision Immuno Oncology Professor, Cleveland Clinic College of Medicine Staff, Radiation Oncology, Taussig Cancer Institute Cleveland Clinic
11:30 AM - 12:00 PM	Roundtable Discussion	Michel Sadelain, MD, PhD; Elizabeth Jaffee, MD; Timothy Chan, MD, PhD; Benjamin Youngblood, PhD; Stephen Gottschalk, PhD; Doug Green, PhD